A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design-Reference-Cited by-同舟云学术

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design

Published:2012-11 Issue:6 Volume:13 Page:505-509
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Garon Edward B.,Cao Dachuang,Alexandris Ekaterine,John William J.,Yurasov Sergey,Perol Maurice

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors;Verheul;Clin Breast Cancer,2000

2. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors;Mukhopadhyay;Semin Cancer Biol,2004

3. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies;Gerber;Cancer Res,2005

4. Antiangiogenesis agents;Folkman,2005

5. Lessons from phase III clinical trials on anti-VEGF therapy for cancer;Jain;Nat Clin Pract Oncol,2006

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF;European Journal of Pharmacology;2023-06

2. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review;Cell Communication and Signaling;2022-04-07

3. Landscape of Immunotherapy in Lung Cancer;Cancer Metastasis Through the Lymphovascular System;2022

4. Long-term response with low-dose of apatinib combined with S-1 in pretreated patient with advanced squamous cell lung cancer;Medicine;2021-02-26

5. Nephrotic syndrome associated with ramucirumab therapy;Medicine;2019-07